William Blair analyst Andrew Brackmann has maintained their bullish stance on DGX stock, giving a Buy rating on October 17.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Andrew Brackmann has given his Buy rating due to a combination of factors that highlight Quest Diagnostics’ strong performance and promising outlook. The company delivered positive results in its third-quarter report, surpassing expectations across key metrics. This performance was driven by several favorable trends, including increased utilization, stable pricing, and successful mergers and acquisitions.
Quest Diagnostics also demonstrated impressive organic revenue growth, which exceeded consensus estimates. The company’s adjusted operating margin and earnings per share were in line with or above expectations, further solidifying its financial health. Additionally, the company raised its full-year guidance, indicating confidence in continued growth. These factors collectively justify the premium valuation of Quest Diagnostics’ shares, supporting the Buy rating.
In another report released on October 17, Mizuho Securities also maintained a Buy rating on the stock with a $210.00 price target.